STP CE Course: Optimizing Toxicologic Pathology Data: Fundamental Concepts and Recommended Practices

When:  Aug 26, 2022 from 12:00 to 15:45 (ET)

This program has been approved for 4.00 hours of continuing education credit in jurisdictions that recognize RACE approval.

 

Optimizing Toxicologic Pathology Data: Fundamental Concepts and Recommended Practices

(Sponsored by the American College of Toxicology)

Friday, August 26, 2022, 12:00 Noon–3:45 PM EDT

Co-Chairs: Daniel J. Patrick, DVM, DACVP, DABT, Eli Lilly & Company; and Noel D. Horton, PhD, DABT, Inotiv

It is well known that successful preclinical safety assessment studies depend on reliable and accurate data, which usually include critical contributions from anatomic and clinical pathology. There are numerous pathology publications that provide insights and recommendations that reliably improve pathology data and overall study outcomes when implemented. This Continuing Education course will present 10 of the most important pathology-related concepts, with practical recommendations that toxicologists can utilize in their preclinical studies. These concepts include using recommended anatomic and clinical pathology study designs, communicating information with the study pathologist before the evaluation, understanding what constitutes a properly trained toxicologic pathologist, following recommended histopathology evaluation practices, appropriately determining the adversity of pathology data, using pathology diagnostic terminology that is globally harmonized and Standard for Exchange of Nonclinical Data (SEND) compliant, knowing when and when not to use pathology historical control data, implementing pathology quality control measures such as pathology peer review, and following recommended pathology reporting practices. This course will be presented by globally recognized toxicologic pathologists who have actively promoted and authored publications on these topics.

Recommended Anatomic and Clinical Pathology Study Designs and Prestudy Communication
Armando R. Irizarry, DVM, PhD, DACVP, Eli Lilly and Company

Prudent Practices for Prepping Pathologists, Handling Histopathology, and Assigning Adversity
Brad Bolon, DVM, MS, PhD, DACVP, DABT, ATS, FIATP, FRCPath, GEMpath Inc.

SENDing the Pathology Data We Have INHAND and Factors to Consider When Using Pathology Historical Control Data
Charlotte M. Keenan, VMD, C.M. Keenan ToxPath Consulting

Histopathology Quality Control and the Reporting of Pathology Data and Interpretations
James D. Fikes, DVM, PhD, DABVT, DACVP, Biogen

Registration
Registration is required to access the course.